Published in Int J Cancer on May 15, 1978
Characterization of an inhibitor of cell division released in tumour cell cultures. Clin Exp Immunol (1980) 1.03
Circulating immune complexes in carcinoma of uterine cervix. Clin Exp Immunol (1979) 0.75
Detection of a low-molecular-weight antigen on melanoma cells by a human antiserum in leukocyte-dependent antibody assays. Br J Cancer (1979) 0.75
Comparison of two methods of screening for genital chlamydial infection in women attending in general practice: cross sectional survey. BMJ (1997) 5.29
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
The care of the dying. Med J Aust (1972) 2.58
A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess (2005) 2.42
Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. J Am Coll Surg (1995) 2.38
Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol (2004) 2.36
Factors involved in presentation of older people with thick melanoma. Med J Aust (1998) 2.20
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg (1982) 2.09
Studies on the sensory hairs of receptor cells in the inner ear. Acta Otolaryngol (1977) 2.02
Characterization of mononuclear effector cells in human blood. Clin Exp Immunol (1976) 1.96
Effects of cigarette smoking on the immune system. Follow-up studies in normal subjects after cessation of smoking. Med J Aust (1983) 1.94
Resection margins for melanoma. Aust N Z J Surg (1985) 1.92
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res (1999) 1.88
Delayed brachial plexus paralysis due to subclavian pseudoaneurysm after clavicular fracture. Eur J Cardiothorac Surg (1993) 1.86
Management of major biliary complications after laparoscopic cholecystectomy. Ann Surg (1993) 1.81
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76
Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer (1979) 1.75
Which adolescents attend the GP? Br J Gen Pract (1997) 1.71
Sequence analysis of the GntII (subsidiary) system for gluconate metabolism reveals a novel pathway for L-idonic acid catabolism in Escherichia coli. J Bacteriol (1998) 1.70
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol (1998) 1.63
Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg (1982) 1.62
Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology (1980) 1.61
Structural family versus psychodynamic child therapy for problematic Hispanic boys. J Consult Clin Psychol (1989) 1.53
Low insertion of hepatic segmental duct VII-VIII is an important cause of major biliary injury or misdiagnosis. Am J Surg (1996) 1.53
Prognostic significance of the histological features of malignant melanoma. Histopathology (1979) 1.51
Acceptability of shared care for asymptomatic HIV-positive patients. Fam Pract (1995) 1.51
Students' perceptions of the relative advantages and disadvantages of community-based and hospital-based teaching: a qualitative study. Med Educ (2000) 1.50
Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J (1973) 1.50
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol (2001) 1.49
Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells. Int J Cancer (1975) 1.48
The involvement of general practitioners in the care of patients with human immunodeficiency virus infection: current practice and future implications. Fam Pract (1993) 1.47
Superior oblique paralysis. A review of 270 cases. Arch Ophthalmol (1986) 1.45
Donated ovarian tissue: the public's view. Lancet (1994) 1.41
Endocrine influences on survival from malignant melanoma. Cancer (1978) 1.40
Thoughts in mind of a person with cancer. Br Med J (1973) 1.40
Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine. Clin Exp Immunol (1974) 1.39
Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res (2001) 1.39
Prognostic histopathological factors in malignant melanoma. Pathology (1985) 1.39
Oxygen wastage from anaesthetic machines. Anaesthesia (2007) 1.38
Immunological effects of solarium exposure. Lancet (1983) 1.38
Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol (2000) 1.37
Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer (1994) 1.35
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett (2000) 1.31
Intestinal disaccharidase activity in rosacea. Br Med J (1966) 1.28
Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg (1991) 1.26
An analysis of a melanoma epidemic. Int J Cancer (1993) 1.25
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer (1985) 1.24
Influence on general practitioners of teaching undergraduates: qualitative study of London general practitioner teachers. BMJ (1999) 1.23
Previous pregnancy as a protective factor against death from melanoma. Lancet (1977) 1.23
Self-willed death or the bone-pointing syndrome. Lancet (1973) 1.22
Low natural-killer-cell activity in familial melanoma patients and their relatives. Br J Cancer (1979) 1.22
Thin malignant melanomas and recurrence potential. Arch Surg (1987) 1.21
Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer (2007) 1.20
Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer (1995) 1.20
Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I). Br J Surg (1980) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol (1983) 1.17
Lymphocyte-dependent cytotoxic antibody activity against human transplantation antigens. Transplantation (1973) 1.17
Late relapse from cutaneous stage I malignant melanoma. Arch Surg (1985) 1.16
Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ (2005) 1.15
The separation and 51 chromium labeling of human lymphocytes with in vivo studies of survival and migration. Blood (1971) 1.15
The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer (1998) 1.15
Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer (1996) 1.15
Histologic features of tumors and the female superiority in survival from malignant melanoma. Cancer (1980) 1.14
Malignant melanoma: influence of site of lesion and age of patient in the female superiority in survival. Cancer (1980) 1.14
Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet (1988) 1.13
Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol (2005) 1.13
The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol (2001) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene (2012) 1.11
Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol (1997) 1.10
Utility of adjuvant systemic therapy in melanoma. Ann Oncol (2009) 1.10
Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer (2009) 1.09
Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology (1983) 1.08
Cytotoxicity against human leukaemic cells. I. Demonstration of antibody-dependent lymphocyte killing of human allogeneic myeloblasts. Clin Exp Immunol (1973) 1.08
Malignant melanoma and vitiligo. Australas J Dermatol (1971) 1.07
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med (1982) 1.06
Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures. Cancer Immunol Immunother (1986) 1.06
Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res (2001) 1.06
Alteration of T cell subsets and induction of suppressor T cell activity in normal subjects after exposure to sunlight. J Immunol (1983) 1.06
Bsp24I, a new unusual restriction endonuclease. Gene (1993) 1.05
CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem Biophys Res Commun (1996) 1.05
The chemoresistance of human malignant melanoma: an update. Melanoma Res (1999) 1.05
Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res (1985) 1.05
Adaptive e-learning to improve dietary behaviour: a systematic review and cost-effectiveness analysis. Health Technol Assess (2011) 1.04
Occult primary malignant melanoma: factors influencing survival. Br J Surg (1977) 1.04
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res (1993) 1.04
Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest (1993) 1.04
The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene (2010) 1.04
General practitioner screening for melanoma: sensitivity, specificity, and effect of training. J Med Screen (1998) 1.03
Characterization of an inhibitor of cell division released in tumour cell cultures. Clin Exp Immunol (1980) 1.03
Evidence-based education: development of an instrument to critically appraise reports of educational interventions. Med Educ (1999) 1.03
Characterization of a novel transporter family that includes multiple Escherichia coli gluconate transporters and their homologues. FEMS Microbiol Lett (1997) 1.03